Novavax Inc

Novavax faces activist pressure and seeks investor confidence amid a booming global COVID‑19 vaccine market, exploring strategy shifts to unlock growth.

Novavax Inc. is experiencing a surge in investor optimism due to a combination of activist investor engagement, analyst upgrades, and strategic partnerships, positioning the company for potential growth and increased valuation.

Novavax has expanded its collaboration with Sanofi, granting the French pharmaceutical company rights to use Novavax’s proprietary Matrix-M adjuvant in its pandemic influenza vaccine candidate program.

Novavax Inc. is preparing to release its Q2 2025 earnings, amidst a mixed bag of financial news, including price target adjustments and a cautious market sentiment.

Novavax, Inc. is a clinical-stage biotechnology company pioneering innovative virus-like particle technology to prevent and treat infectious diseases worldwide.

Novavax Inc.’s stock has experienced significant fluctuations in 2025, following the FDA’s approval of its COVID-19 vaccine, Nuvaxovid, which has sparked both optimism and skepticism among investors and analysts.

Novavax Inc’s stock surged 17% after the FDA approved its COVID-19 vaccine, Nuvaxovid, but analysts remain divided on the company’s long-term prospects.

Novavax Inc.’s stock surged after a strong Q1 performance, beating earnings estimates and boosting revenue, with the company’s optimistic outlook and strategic initiatives positioning it for future growth.

Novavax Inc. is at a critical juncture as it prepares for its Q1 2025 earnings release, with its ability to navigate financial challenges and leverage strategic partnerships crucial to determining its future trajectory in the biotechnology sector.